A Multi-Center, Open-Label, Randomized, Parallel-Controlled Phase II Study Comparing Pharmacokinetic, Pharmacodynamics and Safety of Ripertamab (SCT400) to Rituximab (mabthera in Patients with CD20-positive B-cell Non-Hodgkin Lymphoma
Chinese Journal of Cancer Research（2022）
Key words
Anti-CD20 monoclonal antibody,non-Hodgkin lymphoma,pharmacokinetics,ripertamab,rituximab,safety
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined